{"disease":{"id":"pulmonary-disease","name":"pulmonary disease"},"drugs":{"marketed":[{"drug_id":"budesonide","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"tiotropium-bromide","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spiriva","generic_name":"TIOTROPIUM BROMIDE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":10,"revenue":"2500","mechanism":"Spiriva works by blocking the action of a chemical called acetylcholine, which causes airway muscles to contract and narrow the airways."},{"drug_id":"salbutamol","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proventil","generic_name":"salbutamol","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"albuterol","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ProAir","generic_name":"albuterol","company_name":"Generic (originally Allen & Hanburys/GSK)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"SABA (Short-acting beta-2 agonist)","quality_score":56,"revenue":null,"mechanism":"Short-acting beta-2 adrenergic agonist (SABA) that relaxes bronchial smooth muscle, providing rapid relief of bronchospasm."},{"drug_id":"test-formulation-treatment-a","indication_name":"Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"ensifentrine","indication_name":"chronic obstructive pulmonary disease (COPD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ohtuvayre","generic_name":"ENSIFENTRINE","company_name":"Verona Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Phosphodiesterase 3 Inhibitor [EPC]","quality_score":47,"revenue":null,"mechanism":"Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs."},{"drug_id":"theophyllin","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"carbocysteine","indication_name":"Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mucodyne","generic_name":"carbocysteine","company_name":"","drug_phase":"marketed","molecular_target":"Mucus glycoprotein synthesis","drug_class":"Mucolytic","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"ipratropium","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atrovent","generic_name":"IPRATROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"amikacin","indication_name":"Nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacteriumavium complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"diprophylline","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"terbutaline","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brethine","generic_name":"TERBUTALINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"terbutaline","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"daxas","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daxas","company_name":"AstraZeneca","drug_phase":"phase_2","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"roflumilast","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daliresp","generic_name":"ROFLUMILAST","company_name":"Arcutis","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":63,"revenue":null,"mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body."},{"drug_id":"formoterol","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."}],"pipeline":[{"drug_id":"scopolamine","indication_name":"Chronic obstructive pulmonary disease (COPD)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SCOPOLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors","drug_class":"Anticholinergic [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":21,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06053541","title":"Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change","phase":"","overall_status":"COMPLETED","enrollment_count":3015000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04206098","title":"Chart Review of Patients With COPD, Using Electronic Medical Records and Artificial Intelligence","phase":"","overall_status":"UNKNOWN","enrollment_count":2500000,"lead_sponsor_name":"Sociedad Española de Neumología y Cirugía Torácica","has_results":false},{"nct_id":"NCT04506528","title":"COVID EHR COHORT at the University of Wisconsin","phase":"","overall_status":"COMPLETED","enrollment_count":1634381,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT04926233","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","phase":"","overall_status":"COMPLETED","enrollment_count":1371146,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05813652","title":"Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":919928,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT05480176","title":"The China National COPD Screening Program","phase":"","overall_status":"UNKNOWN","enrollment_count":800000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT04135404","title":"Factors That Impact the Relationship Between Pulmonary Status and Actual Electronic Cigarette Use","phase":"","overall_status":"COMPLETED","enrollment_count":400000,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT07416266","title":"Lower Respiratory Tract Infections Managed in Primary Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":230066,"lead_sponsor_name":"Hôpital Raymond Poincaré","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT02612688","title":"Pragmatic Trial of Video Education in Nursing Homes","phase":"NA","overall_status":"COMPLETED","enrollment_count":197692,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT05457868","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists","phase":"","overall_status":"COMPLETED","enrollment_count":124117,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05179512","title":"Replication of the INSPIRE Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":98278,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03405363","title":"Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists","phase":"","overall_status":"COMPLETED","enrollment_count":65406,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04966637","title":"Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data","phase":"","overall_status":"COMPLETED","enrollment_count":54028,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT06523270","title":"Advanced Imaging Holistic Omics Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05781581","title":"A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04684836","title":"Comparative Effectiveness of Telemedicine in Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":33100,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03030638","title":"Drug Utilization Study for Olodaterol","phase":"","overall_status":"COMPLETED","enrollment_count":27606,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04184297","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":27190,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03290287","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","phase":"","overall_status":"COMPLETED","enrollment_count":26839,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03242109","title":"The Moli-sani Study","phase":"","overall_status":"COMPLETED","enrollment_count":24325,"lead_sponsor_name":"Neuromed IRCCS","has_results":false},{"nct_id":"NCT06744374","title":"A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)","phase":"","overall_status":"COMPLETED","enrollment_count":22369,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03333018","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","phase":"","overall_status":"COMPLETED","enrollment_count":22155,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07332156","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","phase":"","overall_status":"COMPLETED","enrollment_count":21692,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05393245","title":"Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data","phase":"","overall_status":"COMPLETED","enrollment_count":19467,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05497999","title":"Racial Inequality in Inhaler Fills for COPD - A Trial of Reduced Cost-Sharing","phase":"NA","overall_status":"COMPLETED","enrollment_count":19113,"lead_sponsor_name":"Harvard Medical School (HMS and HSDM)","has_results":false},{"nct_id":"NCT04097223","title":"A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)","phase":"","overall_status":"COMPLETED","enrollment_count":17464,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05402020","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":17018,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT01313676","title":"Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16568,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT06763549","title":"COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15000,"lead_sponsor_name":"Peerbridge Health, Inc","has_results":false},{"nct_id":"NCT05069194","title":"Study on the Etiology, Risk Factors and Pathogenesis of COPD Based on Clinical Bioinformatics","phase":"","overall_status":"UNKNOWN","enrollment_count":13000,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06742736","title":"EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)","phase":"","overall_status":"COMPLETED","enrollment_count":13000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02760329","title":"Observational Study of Obstructive Lung Disease (NOVELTY)","phase":"","overall_status":"COMPLETED","enrollment_count":12255,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05127304","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","phase":"","overall_status":"COMPLETED","enrollment_count":11316,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03979807","title":"A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)","phase":"","overall_status":"COMPLETED","enrollment_count":11296,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03365713","title":"GECo: Implementation and Effectiveness of COPD Case-Finding in Low and Middle Income Countries","phase":"","overall_status":"COMPLETED","enrollment_count":10709,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06685315","title":"Research on the Characteristics of Chronic Airway Diseases (asthma, COPD)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10545,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT02164513","title":"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10355,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03359122","title":"Association of COPD Maintenance Medication Adherence With Resource Use and Cost Among COPD Patients","phase":"","overall_status":"COMPLETED","enrollment_count":10067,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07382986","title":"IMPACT COPD Cohort (China)","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Chao Yang Hospital","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT07217522","title":"Rutgers University Study of the Genetics of Pulmonary Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05382572","title":"Pulmonary Fibrosis Foundation Community Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT07267117","title":"Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03893409","title":"GIRH Chronic Obstructive Pulmonary Disease Observational Study","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"zili zhang","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}